



CHARGÉ DE MISSION SCIENTIFIQUE

BERNARD TARDY

PUPH Thérapeutique (section CNU 48-04)

Bernard Tardy est PUPH Thérapeutique (section CNU 48-04) depuis 2008. Il occupe également des fonctions Hospitalo-Universitaires, en tant que Responsable de l'Unité de soins continus médicaux (Hôpital Nord, CHU St Etienne) et Coordinateur du Centre d'investigation Clinique (Inserm CIC 1408) de Saint Etienne depuis 2014 (coordinateur adjoint de 2003 à 2013).

Autres responsabilités exercées

- Président du CRBSP du CHU de Saint Etienne
- Membre du bureau national des CIC
- Membre de l'équipe DVH au sein de l'UMR1059 SAINBIOSE, Université Jean Monnet, PRES de Lyon, Saint- Etienne, France

Principales publications

- Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study. Tardy B, Picard S, Guirimand F, Chapelle C, Danel Delerue M, Celarier T, Ciais JF, Vassal P, Salas S, Filbet M, Gomas JM, Guillot A, Gaultier JB, Merah A, Richard A, Laporte S, Bertoletti L. *J Thromb Haemost.* 2017 Mar;15(3):420-428
- Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Robin P, Le Roux PY, Planquette B, Accassat S, Roy PM, Couturaud F, Ghazzar N, Prevot-Bitot N, Couturier O, Delluc A, Sanchez O, Tardy B, Le Gal G, Salaun PY; MVTEP study group. *Lancet Oncol.* 2016 Feb;17(2):193-9
- Transient and Persistent Acute Kidney Injury and the Risk of Hospital Mortality in Critically Ill Patients: Results of a Multicenter Cohort Study. Perinel S, Vincent F, Lautrette A, Dellamonica J, Mariat C, Zeni F, Cohen Y, Tardy B, Souweine B, Darmon M. *Crit Care Med.* 2015 Aug;43(8):e269-75
- Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs. Chalayer E, Chapelle C, Leleu X, Elalamy I, Laporte S, Tardy B. *Am J Hematol.* 2016 Oct;91(10):E455-6
- Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. Mismetti P, Laporte S, Pellerin O, Ennezat PV, Couturaud F, Elias A, Falvo N, Meneveau N, Quere I, Roy PM, Sanchez O, Schmidt J, Seinturier C, Sevestre MA, Beregi JP, Tardy B, Lacroix P, Presles E, Leizorovicz A, Decousus H, Barral FG, Meyer G; PREPIC2 Study Group. *JAMA.* 2015 Apr 28;313(16):1627



- Performance of ¹⁸F fluoro-2-désoxy-D-glucose positron em1ssion tomography/computed tomography for the diagnosis of venous thromboembolism. Le Roux PY, Robin P, Delluc A, Tardy B, Abgral R, Couturaud F, Reffad A, Le Gal G, Salaun PY. Thromb Res. 2015 Jan;135(1):31-5
- Delayed-onset heparin-induced thrombocytopenia without thrombosis in a patient receiving postoperative thromboprophylaxis with rivaroxaban. Tardy-Poncet B, Piot M, Montmartin A, Burdier A, Chalayer E, Tardy B. Thromb Haemost. 2015 Aug 31;114(3):652-4
- Frappé P, Buchmuller-Cordier A, Bertoletti L, Bonithon-Kopp C, Couzan S, Lafond P, Leizorovicz A, Merah A, Presles E, Preynat P, Tardy B, Décousus H; The STEPH Study Group. Annual diagnosis rate of superficial-vein thrombosis of the Lower limbs: the STEPH community-based study. J Thromb Haemost 2014 Jun;12(6):831-8
- The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials. Tardy B, Chalayer E, Chapelle C, Mismetti P. J Thromb Haemost. 2014 Sep; 12(9): 1572-3
- Fibrinolysis for patients with intermediate-risk pulmonary embolism. Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Deltas C, Empen K, Franca A, Galiè N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczak P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren F, Konstantinides SV; PEITHO Investigators. N Engl J Med. 2014 Apr 10;370(15):1402-11